ALOPECIA AREATA

ALOPECIA AREATA STUDY (169 WEEEKS)

Adults 18 to less than 64 years old who have a diagnosis of severe alopecia areata (AA) with 50% or more scalp hair loss, may qualify for this clinical research trial and receive investigational oral medication (active study drug) or placebo.
Eligible participants must have severe AA with no spontaneous scalp hair regrowth over the past 6 months AND no significant scalp hair loss over the past 3 months, have current episode of AA of less than 8 years, not have a diagnosis of primarily diffuse type of AA, and not have a diagnosis of other types of alopecia.

Participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 16 times (plus a 30-day follow-up phone call or a site visit) over a period of about 169 weeks.

For further information on the study, please follow the link: 

Study Details | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata | ClinicalTrials.gov

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigators
Dr Issac Lee

Dr Nisal Punchihewa
t: 9623 9464
e: [email protected]

Study Coordinator
Irina Danilovich
p: 9623 9448
e: [email protected]